Renauld J C
Ludwig Institute for Cancer Research and Experimental Medicine Unit, Université Catholique de Louvain, B-1200 Brussels, Belgium.
J Clin Pathol. 2001 Aug;54(8):577-89. doi: 10.1136/jcp.54.8.577.
Asthma is a triad of intermittent airway obstruction, bronchial smooth muscle cell hyperreactivity to bronchoconstrictors, and chronic bronchial inflammation. From an aetiological standpoint, asthma is a heterogeneous disease, but often appears as a form of immediate hypersensitivity. Many patients with asthma have other manifestations of atopy, such as rhinitis or eczema. Even among non-atopic patients with asthma, the pathophysiology of airway constriction is similar, raising the hypothesis that alternative mechanisms of mast cell degranulation may underlie the disease. The primary inflammatory lesion of asthma consists of accumulation of CD4(+) T helper type 2 (TH2) lymphocytes and eosinophils in the airway mucosa. TH2 cells orchestrate the asthmatic inflammation through the secretion of a series of cytokines, particularly interleukin 4 (IL-4), IL-13, IL-5, and IL-9. IL-4 is the major factor regulating IgE production by B cells, and is required for optimal TH2 differentiation. However, blocking IL-4 is not sufficient to inhibit the development of asthma in experimental models. In contrast, inhibition of IL-13, another TH2 cytokine whose signal transduction pathway overlaps with that of IL-4, completely blocks airway hyperreactivity in mouse asthma models. IL-5 is a key factor for eosinophilia and could therefore be responsible for some of the tissue damage seen in chronic asthma. IL-9 has pleiotropic activities on allergic mediators such as mast cells, eosinophils, B cells and epithelial cells, and might be a good target for therapeutic interventions. Finally, chemokines, which can be produced by many cell types from inflamed lungs, play a major role in recruiting the mediators of asthmatic inflammation. Genetic studies have demonstrated that multiple genes are involved in asthma. Several genome wide screens point to chromosome 5q31--33 as a major susceptibility locus for asthma and high IgE values. This region includes a cluster of cytokine genes, and genes encoding IL-3, IL-4, IL-5, IL-9, IL-13, granulocyte macrophage colony stimulating factor, and the beta chain of IL-12. Interestingly, for some of these cytokines, a linkage was also established between asthma and their receptor. Another susceptibility locus has been mapped on chromosome 12 in a region that contains other potential candidate cytokine genes, including the gene encoding interferon gamma, the prototypical TH1 cytokine with inhibitory activities for TH2 lymphocytes. Taken together, both experimental and genetic studies point to TH2 cytokines, such as IL-4, IL-13, IL-5, and IL-9, as important targets for therapeutic applications in patients with asthma.
哮喘是一种具有间歇性气道阻塞、支气管平滑肌细胞对支气管收缩剂反应性亢进以及慢性支气管炎症的三联征疾病。从病因学角度来看,哮喘是一种异质性疾病,但常表现为速发型超敏反应的一种形式。许多哮喘患者还有其他特应性表现,如鼻炎或湿疹。即使在非特应性哮喘患者中,气道收缩的病理生理学机制也相似,这就提出了一种假说,即肥大细胞脱颗粒的其他机制可能是该疾病的基础。哮喘的主要炎症病变是气道黏膜中CD4(+)辅助性T细胞2型(TH2)淋巴细胞和嗜酸性粒细胞的积聚。TH2细胞通过分泌一系列细胞因子,特别是白细胞介素4(IL-4)、IL-13、IL-5和IL-9来协调哮喘炎症。IL-4是调节B细胞产生IgE的主要因子,也是TH2细胞最佳分化所必需的。然而,在实验模型中阻断IL-4不足以抑制哮喘的发展。相比之下,抑制IL-13(另一种信号转导途径与IL-4重叠的TH2细胞因子)可完全阻断小鼠哮喘模型中的气道高反应性。IL-5是嗜酸性粒细胞增多的关键因子,因此可能是慢性哮喘中所见某些组织损伤的原因。IL-9对肥大细胞、嗜酸性粒细胞、B细胞和上皮细胞等过敏介质具有多效性作用,可能是治疗干预的一个良好靶点。最后,炎症肺组织中的多种细胞类型均可产生趋化因子,其在募集哮喘炎症介质方面起主要作用。基因研究表明,多个基因与哮喘有关。多项全基因组筛查指出,5号染色体q31 - 33区域是哮喘和高IgE值的主要易感位点。该区域包括一组细胞因子基因,以及编码IL-3、IL-4、IL-5、IL-9、IL-13、粒细胞巨噬细胞集落刺激因子和IL-12β链的基因。有趣的是,对于其中一些细胞因子,还在哮喘与其受体之间建立了联系。另一个易感位点定位于12号染色体上的一个区域,该区域包含其他潜在的候选细胞因子基因,包括编码干扰素γ的基因,干扰素γ是对TH2淋巴细胞具有抑制活性的典型TH1细胞因子。综上所述,实验研究和基因研究均指出,TH2细胞因子,如IL-4、IL-13、IL-5和IL-9,是哮喘患者治疗应用的重要靶点。